Publications by authors named "R LASSER"
J Clin Psychopharmacol
June 2024
Article Synopsis
- Zuranolone is a new treatment for postpartum depression approved for a 14-day course and is being studied for how it transfers into breast milk.
- In this study, lactating participants took a daily dose of 30 mg zuranolone, and the transfer was measured, revealing a relative infant dose (RID) of 0.357% after 5 days.
- The findings suggest that the transfer of zuranolone into breast milk is low and stays well below the 10% threshold that is considered safe for breastfeeding.
J Clin Psychiatry
December 2023
Article Synopsis
- Zuranolone is a new oral treatment for postpartum depression and is being studied for major depressive disorder, acting as a modulator of GABA receptors in the brain.
- The ongoing SHORELINE Study aims to assess the long-term safety and effectiveness of zuranolone in adults with major depressive disorder, with patients undergoing treatment for up to 1 year.
- Preliminary results show that a significant percentage of patients experienced mild to moderate side effects, but there were notable improvements in depression scores after initial and repeat treatments.
Neuropsychopharmacology
January 2024
Article Synopsis
- - Major depressive disorder (MDD) can significantly impact a person's ability to function and traditional antidepressant treatments take weeks to show effects; zuranolone is a new oral treatment that's been approved for postpartum depression and is being studied for MDD.
- - The CORAL Study tested the effectiveness of zuranolone (50 mg) when combined with standard antidepressant therapy against a placebo in 425 adults with MDD, focusing on improvements in depression symptoms within the first three days.
- - Results showed that patients taking zuranolone experienced a greater reduction in depression scores by Day 3 compared to those on placebo, with mild to moderate side effects being the most common, such as drowsiness and headaches.
Am J Psychiatry
September 2023
Article Synopsis
- Postpartum depression (PPD) is a common issue affecting new mothers, and this study explored the effectiveness and safety of zuranolone as a treatment option over a 14-day period.
- In a phase 3 trial with 196 participants, those taking zuranolone showed significant improvements in depression scores compared to those on a placebo, with benefits noted as early as day 3.
- The treatment was well tolerated, with some side effects like somnolence and dizziness, but no serious risks such as loss of consciousness or increased suicidal thoughts were reported.
Am J Psychiatry
September 2023
Article Synopsis
- * Patients in the zuranolone group experienced notable symptom relief as early as day 3, and this improvement was sustained through day 15 and beyond, with a statistically significant change from baseline scores.
- * The treatment was generally well tolerated, with similar rates of serious adverse events in both the zuranolone and placebo groups, suggesting its potential as a viable option for treating major depressive disorder.
